Competitive PressureAnticipated competitive pressure from GLP-1-based therapies impacting future Rezdiffra market penetration/share driven in part by uncertainties to payer coverage policy.
Regulatory ChallengesFailure to obtain FDA or EMA approvals, clinical trial failure, or unforeseen competitive threats could negatively impact stock performance.
Sales And Demand ConcernsNew prescriptions exiting 2Q were significantly lower than patient-modeling estimates, raising concerns about underlying patient demand.